Founded with a mission to innovate cancer treatment, Dracen Pharmaceuticals focuses on developing novel glutamine antagonists aimed at improving outcomes for cancer patients. The company leverages immuno-metabolism to create potential new treatments, specifically targeting advanced solid tumors and fibrolamellar carcinoma. Their market focus is on providing advanced therapeutic options for patients with limited treatment choices, thereby addressing significant unmet medical needs in oncology.
Dracen Pharmaceuticals has notable affiliations, including a clinical collaboration with Merck and support from the Fibrolamellar Cancer Foundation (FCF). Key achievements include the initiation of a first-in-human study of their lead compound, DRP-, and a phase I/II study in combination with Durvalumab for fibrolamellar carcinoma. These milestones underscore Dracen's impact on advancing cancer treatment and their commitment to bringing innovative therapies to market.
